4.6 Article

Altered Expression of Growth Associated Protein-43 and Rho Kinase in Human Patients with Parkinson's Disease

Journal

BRAIN PATHOLOGY
Volume 27, Issue 1, Pages 13-25

Publisher

WILEY
DOI: 10.1111/bpa.12346

Keywords

astrogliosis; GAP-43; microgliosis; Parkinson's disease; regeneration; rho kinase; ROCK; striatum; substantia nigra

Funding

  1. Cluster of Excellence
  2. DFG Research Center Nanoscale Microscopy and Molecular Physiology of the Brain, Gottingen
  3. Else Kroner-Fresenius Stiftung
  4. Swedish Brain Power
  5. Swedish Parkinson Foundation
  6. Swedish Research Council
  7. Parkinson's UK [J-1402] Funding Source: researchfish

Ask authors/readers for more resources

Causative treatment strategies for Parkinson's disease (PD) will have to address multiple underlying pathomechanisms to attenuate neurodegeneration. Additionally, the intrinsic regenerative capacity of the central nervous system is also an important factor contributing to restoration. Extracellular cues can limit sprouting and regrowth of adult neurons, but even aged neurons have a low intrinsic regeneration capacity. Whether this capacity has been lost or if growth inhibitory cues are increased during PD progression has not been resolved yet. In this study, we assessed the regenerative potential in the nigrostriatal system in post-mortem brain sections of PD patients compared to age-matched and young controls. Investigation of the expression pattern of the regeneration-associated protein GAP-43 suggested a lower regenerative capacity in nigral dopaminergic neurons of PD patients. Furthermore, the increase in protein expression of the growth-inhibitory protein ROCK2 in astrocytes and a similar trend in microglia, suggests an important role for ROCK2 in glial PD pathology, which is initiated already in normal aging. Considering the role of astro- and microglia in PD pathogenesis as well as beneficial effects of ROCK inhibition on neuronal survival and regeneration in neurodegenerative disease models, our data strengthens the importance of the ROCK pathway as a therapeutic target in PD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Clinical Neurology

Relevance of COMT inhibitors in the treatment of motor fluctuations

Wolfgang H. Jost, Carsten Buhmann, Joseph Classen, Karla Eggert, Zacharias Kohl, Tiago Outeiro, Lars Tonges, Dirk Woitalla, Heinz Reichmann

Summary: COMT inhibitors have been established for over 20 years in the treatment of motor fluctuations in Parkinson's disease. However, the available inhibitors differ in pharmacokinetics, indication requirements, and side effects, leading to many patients not receiving optimized drug treatment.

NERVENARZT (2022)

Article Clinical Neurology

Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies

Olivier Rascol, Lars Toenges, Tina DeVries, Mark Jaros, Adrian Quartel, David Jacobs

Summary: The study shows that IR/ER amantadine is effective in reducing LID, but the results vary in different doses and trials. However, despite some adverse events, it still has the potential to be an effective medication in the treatment of LID.

PARKINSONISM & RELATED DISORDERS (2022)

Article Neurosciences

L-DOPA administration shifts the stability-flexibility balance towards attentional capture by distractors during a visual search task

P. Riedel, I. M. Domachowska, Y. Lee, P. T. Neukam, L. Tonges, S. C. Li, T. Goschke, M. N. Smolka

Summary: The cognitive control dilemma refers to the balance between stability and flexibility in attention, which is believed to be maintained by dopamine. However, there is limited research on this balance in humans.

PSYCHOPHARMACOLOGY (2022)

Review Biochemistry & Molecular Biology

Update on CSF Biomarkers in Parkinson's Disease

Eun Hae Kwon, Sabrina Tennagels, Ralf Gold, Klaus Gerwert, Leon Beyer, Lars Toenges

Summary: This paper emphasizes the importance of reliable objective markers for identifying individuals at risk of Parkinson's disease. Advances in biomarker discovery, particularly in the cerebrospinal fluid (CSF), have provided promising preliminary results. Potential biomarkers include alpha-synuclein species, markers of amyloid and tau pathology, neurofilament light chain, lysosomal enzymes, and markers of neuroinflammation. Metabolomics approaches have also offered insights into novel biological pathways. Genetic forms of PD can help identify subgroups suitable for targeted treatments. Further validation studies are needed to determine the most valuable CSF biomarkers or combinations for clinical and research purposes.

BIOMOLECULES (2022)

Article Clinical Neurology

Adenosine A2A Receptor Antagonists as a Treatment Option for Parkinson's Disease?

Wolfgang H. Jost, Lars Toenges

Summary: In Parkinson's disease, the focus has traditionally been on motor symptoms and dopaminergic therapy. However, the importance of non-motor symptoms has gained recognition, highlighting the need for treatment of non-dopaminergic deficits. Adenosine A (2A) receptor antagonists have been identified as an additional therapy, as they can modulate the striato-thalamo-cortical loops.

FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE (2022)

Review Clinical Neurology

Blood-based biomarker in Parkinson's disease: potential for future applications in clinical research and practice

Lars Toenges, Carsten Buhmann, Stephan Klebe, Jochen Klucken, Eun Hae Kwon, Thomas Mueller, David J. Pedrosa, Nils Schroeter, Peter Riederer, Paul Lingor

Summary: The clinical presentation of Parkinson's disease is complex and heterogeneous, making precise classification challenging. Currently, research is focused on investigating tissue- and fluid-based biomarkers to improve the understanding of Parkinson's disease. Blood-based biomarkers have great potential for use in clinical practice if they meet the necessary requirements. In this review, the knowledge on blood-based biomarkers for Parkinson's disease is summarized from both a researcher's and clinician's perspective.

JOURNAL OF NEURAL TRANSMISSION (2022)

Letter Clinical Neurology

A Novel NPTX1 de novo Variant in a Late-Onset Ataxia Patient

Jonas Deppe, Natalie Deininger, Paul Lingor, Tobias B. Haack, Bernhard Haslinger, Marcus Deschauer

MOVEMENT DISORDERS (2022)

Article Immunology

Mild COVID-19 imprints a long-term inflammatory eicosanoid-and chemokine memory in monocyte-derived macrophages

Sina Bohnacker, Franziska Hartung, Fiona Henkel, Alessandro Quaranta, Johan Kolmert, Alina Priller, Minhaz Ud-Dean, Johanna Giglberger, Luisa M. Kugler, Lisa Pechtold, Sarah Yazici, Antonie Lechner, Johanna Erber, Ulrike Protzer, Paul Lingor, Percy Knolle, Adam M. Chaker, Carsten B. Schmidt-Weber, Craig E. Wheelock, Julia Esser-von Bieren

Summary: SARS-CoV-2 infection leaves an inflammatory imprint in MDM, resulting in aberrant macrophage function and eicosanoid metabolism, leading to long-term immune aberrations in patients recovering from mild COVID-19.

MUCOSAL IMMUNOLOGY (2022)

Review Geriatrics & Gerontology

Monogenetic Forms of Parkinson's Disease - Bridging the Gap Between Genetics and Biomarkers

Lars Toenges, Eun Hae Kwon, Stephan Klebe

Summary: The therapy of neurodegenerative diseases is limited to symptom treatment, but disease-modifying therapies and early diagnosis offer hope for new neuroprotective treatments. Monogenetic forms of Parkinson's disease are likely to benefit from disease-modifying therapies, and biomarkers are crucial for diagnosis and monitoring treatment in clinical trials.

FRONTIERS IN AGING NEUROSCIENCE (2022)

Article Neurosciences

Impact of the COVID-19 Pandemic on Patients with Parkinson's Disease from the Perspective of Treating Physicians-A Nationwide Cross-Sectional Study

Andreas Wolfgang Wolff, Bernhard Haller, Antonia Franziska Demleitner, Erica Westenberg, Paul Lingor

Summary: The COVID-19 pandemic has had a significant impact on the medical care of patients with Parkinson's disease, leading to worsening symptoms, appointment cancellations, and difficulties in organizing treatments. Physicians offered alternative consultation options, with telephone consultations being the most accepted by patients.

BRAIN SCIENCES (2022)

Review Neurosciences

SARS-CoV-2, COVID-19 and Parkinson's Disease-Many Issues Need to Be Clarified-A Critical Review

Tsepo Goerttler, Eun-Hae Kwon, Michael Fleischer, Mark Stettner, Lars Tonges, Stephan Klebe

Summary: The review examines the impact of SARS-CoV-2 and COVID-19 syndrome on Parkinson's disease patients, discussing symptoms, treatment, and the possibility of the virus causing PD. Additionally, it explores the consequences for asymptomatic and non-affected PD patients, as well as the potential connection between COVID syndrome and PD.

BRAIN SCIENCES (2022)

Article Clinical Neurology

Parkinson's disease multimodal complex treatment improves gait performance: an exploratory wearable digital device-supported study

Raphael Scherbaum, Andreas Moewius, Judith Oppermann, Johanna Geritz, Clint Hansen, Ralf Gold, Walter Maetzler, Lars Toenges

Summary: This study found that wearable device-based parameters (DBP) can objectively describe gait and balance impairment in Parkinson's disease (PD) and are correlated with clinical scores. PD-MCT significantly improves gait velocity and stride length and has a positive impact on other DBP. Motor complications and fear of falling may influence the response to PD-MCT. The results of this study suggest that a DBP-based assessment can provide more individualized therapy and improve outcomes for PD patients.

JOURNAL OF NEUROLOGY (2022)

Article Medicine, General & Internal

Trial of Cinpanemab in Early Parkinson's Disease

A. E. Lang, A. D. Siderowf, E. A. Macklin, W. Poewe, D. J. Brooks, H. H. Fernandez, O. Rascol, N. Giladi, F. Stocchi, C. M. Tanner, R. B. Postuma, D. K. Simon, E. Tolosa, B. Mollenhauer, J. M. Cedarbaum, K. Fraser, J. Xiao, K. C. Evans, D. L. Graham, I Sapir, J. Inra, R. M. Hutchison, M. Yang, T. Fox, S. Budd Haeberlein, T. Dam

Summary: In participants with early Parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in DaT-SPECT imaging did not differ from those of placebo over a 52-week period.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Article Clinical Neurology

Data-driven subtyping of Parkinson's disease: comparison of current methodologies and application to the Bochum PNS cohort

Qiang Chen, Raphael Scherbaum, Ralf Gold, Kalliopi Pitarokoili, Axel Mosig, Samis Zella, Lars Toenges

Summary: A data-driven clustering analysis was conducted to identify three subtypes of Parkinson's disease: early onset mild type, intermediate type, and late-onset severe type. The Parkinson's Disease Questionnaire (PDQ-39), Non-motor Symptom Questionnaire (NMSQuest), and the MDS-UPDRS Part II were found to be crucial factors for differentiating PD subtypes.

JOURNAL OF NEURAL TRANSMISSION (2023)

Article Biochemistry & Molecular Biology

Quality Control-A Stepchild in Quantitative Proteomics: A Case Study for the Human CSF Proteome

Svitlana Rozanova, Julian Uszkoreit, Karin Schork, Bettina Serschnitzki, Martin Eisenacher, Lars Toenges, Katalin Barkovits-Boeddinghaus, Katrin Marcus

Summary: Proteomic studies using mass spectrometry (MS)-based quantification are important for discovering new biomarkers, but the accuracy of the outcomes can be affected by various analytical conditions. Therefore, it is crucial to assess the quality of the acquired data, including raw data, identification, and quantification levels. This study demonstrates the assessment of four independent datasets from cerebrospinal fluid, highlighting the impact of sample processing-based differences on the quality of quantitative data. Additionally, a free and open source quality control tool called MaCProQC is provided for systematic and rapid data comparison.

BIOMOLECULES (2023)

No Data Available